首页 > 最新文献

Therapeutic Advances in Chronic Disease最新文献

英文 中文
Development of the ESEx index: a tool for predicting risk of recurrent severe COPD exacerbations. ESEx指数的发展:一种预测复发性严重COPD恶化风险的工具
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-02-28 eCollection Date: 2023-01-01 DOI: 10.1177/20406223231155115
Elisa Valera-Novella, Roberto Bernabeu-Mora, Joaquina Montilla-Herrador, Pilar Escolar-Reina, José Antonio García-Vidal, Francesc Medina-Mirapeix

Background: In chronic obstructive pulmonary disease (COPD), multiple recurrent severe exacerbations that require hospitalization can occur. These events are strongly associated with death and other clinical complications.

Objectives: We aimed to develop a prognostic model that could identify patients with COPD that are at risk of multiple recurrent severe exacerbations within 3 years.

Design: Prospective cohort.

Methods: The derivation cohort comprised patients with stable, moderate-to-severe COPD. Multivariable logistic regression analyses were performed to develop the final model. Based on regression coefficients, a simplified index (ESEx) was established. Both, model and index, were assessed for predictive performance by measuring discrimination and calibration.

Results: Over 3 years, 16.4% of patients with COPD experienced at least three severe recurrent exacerbations. The prognostic model showed good discrimination of high-risk patients, based on three characteristics: the number of severe exacerbations in the previous year, performance in the five-repetition sit-to-stand test, and in the 6-minute-walk test. The ESEx index provided good level of discrimination [areas under the receiver operating characteristic curve (AUCs): 0.913].

Conclusions: The ESEx index showed good internal validation for the identification of patients at risk of three recurrent severe COPD exacerbations within 3 years. These tools could be used to identify patients who require early interventions and motivate patients to improve physical performance to prevent recurrent exacerbations.

在慢性阻塞性肺病(COPD)中,可能会出现需要住院治疗的多次复发性严重急性加重。这些事件与死亡和其他临床并发症密切相关。我们旨在开发一种预后模型,该模型可以识别COPD患者在3年内有多次复发严重急性加重的风险。前瞻性队列。衍生队列包括稳定、中度至重度COPD患者。进行多变量逻辑回归分析以开发最终模型。基于回归系数,建立了简化指数ESEx。通过测量判别和校准,对模型和指数的预测性能进行了评估。在3年的时间里,16.4%的COPD患者经历了至少三次严重的复发性加重。预后模型根据三个特征对高危患者进行了良好的区分:前一年严重恶化的次数、五次重复坐-站测试和6分钟步行测试的表现。ESEx指数提供了良好的判别水平[受试者工作特征曲线下面积(AUCs):0.913]。ESEx指数显示出良好的内部验证,可用于识别3年内有三次复发性严重COPD恶化风险的患者。这些工具可用于识别需要早期干预的患者,并激励患者改善身体表现,以防止复发性加重。
{"title":"Development of the ESEx index: a tool for predicting risk of recurrent severe COPD exacerbations.","authors":"Elisa Valera-Novella, Roberto Bernabeu-Mora, Joaquina Montilla-Herrador, Pilar Escolar-Reina, José Antonio García-Vidal, Francesc Medina-Mirapeix","doi":"10.1177/20406223231155115","DOIUrl":"10.1177/20406223231155115","url":null,"abstract":"<p><strong>Background: </strong>In chronic obstructive pulmonary disease (COPD), multiple recurrent severe exacerbations that require hospitalization can occur. These events are strongly associated with death and other clinical complications.</p><p><strong>Objectives: </strong>We aimed to develop a prognostic model that could identify patients with COPD that are at risk of multiple recurrent severe exacerbations within 3 years.</p><p><strong>Design: </strong>Prospective cohort.</p><p><strong>Methods: </strong>The derivation cohort comprised patients with stable, moderate-to-severe COPD. Multivariable logistic regression analyses were performed to develop the final model. Based on regression coefficients, a simplified index (ESEx) was established. Both, model and index, were assessed for predictive performance by measuring discrimination and calibration.</p><p><strong>Results: </strong>Over 3 years, 16.4% of patients with COPD experienced at least three severe recurrent exacerbations. The prognostic model showed good discrimination of high-risk patients, based on three characteristics: the number of severe exacerbations in the previous year, performance in the five-repetition sit-to-stand test, and in the 6-minute-walk test. The ESEx index provided good level of discrimination [areas under the receiver operating characteristic curve (AUCs): 0.913].</p><p><strong>Conclusions: </strong>The ESEx index showed good internal validation for the identification of patients at risk of three recurrent severe COPD exacerbations within 3 years. These tools could be used to identify patients who require early interventions and motivate patients to improve physical performance to prevent recurrent exacerbations.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"1 1","pages":"20406223231155115"},"PeriodicalIF":3.5,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44740236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases. 植物大麻素如何影响心血管健康?最常见心血管疾病的最新情况。
IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-06 eCollection Date: 2023-01-01 DOI: 10.1177/20406223221143239
Sylwia Dziemitko, Ewa Harasim-Symbor, Adrian Chabowski

Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients with CVD, some limitations, including drug complications, still exist. Hence, the endocannabinoid system (ECS) was proposed as a new avenue for CVDs treatment. The ECS components are widely distributed through the body, including the heart and blood vessels, thus the action of its endogenous and exogenous ligands, in particular, phytocannabinoids play a key role in various pathological states. The cardiovascular action of cannabinoids is complex as they affect vasculature and myocardium directly via specific receptors and exert indirect effects through the central and peripheral nervous system. The growing interest in phytocannabinoid studies, however, has extended the knowledge about their molecular targets as well as therapeutical properties; nonetheless, some areas of their actions are not yet fully recognized. Researchers have reported various cannabinoids, especially cannabidiol, as a promising approach to CVDs; hence, the purpose of this review is to summarize and update the cardiovascular actions of the most potent phytocannabinoids and the potential therapeutic role of ECS in CVDs, including ischemic reperfusion injury, arrhythmia, heart failure as well as hypertension.

心血管疾病(CVD)每年在全球造成数百万人死亡。尽管针对心血管疾病患者的疗法取得了巨大进步,但仍存在一些局限性,包括药物并发症。因此,有人提出将内源性大麻素系统(ECS)作为治疗心血管疾病的新途径。ECS 成分广泛分布于全身,包括心脏和血管,因此其内源性和外源性配体,特别是植物大麻素的作用在各种病理状态中发挥着关键作用。大麻素对心血管的作用非常复杂,因为它们通过特定受体直接影响血管和心肌,并通过中枢和外周神经系统发挥间接作用。然而,人们对植物大麻素研究的兴趣与日俱增,扩大了对其分子靶点和治疗特性的了解;然而,人们对其作用的某些领域尚未完全认识。因此,本综述旨在总结和更新最有效植物大麻素的心血管作用以及 ECS 在心血管疾病(包括缺血再灌注损伤、心律失常、心力衰竭和高血压)中的潜在治疗作用。
{"title":"How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases.","authors":"Sylwia Dziemitko, Ewa Harasim-Symbor, Adrian Chabowski","doi":"10.1177/20406223221143239","DOIUrl":"10.1177/20406223221143239","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients with CVD, some limitations, including drug complications, still exist. Hence, the endocannabinoid system (ECS) was proposed as a new avenue for CVDs treatment. The ECS components are widely distributed through the body, including the heart and blood vessels, thus the action of its endogenous and exogenous ligands, in particular, phytocannabinoids play a key role in various pathological states. The cardiovascular action of cannabinoids is complex as they affect vasculature and myocardium directly <i>via</i> specific receptors and exert indirect effects through the central and peripheral nervous system. The growing interest in phytocannabinoid studies, however, has extended the knowledge about their molecular targets as well as therapeutical properties; nonetheless, some areas of their actions are not yet fully recognized. Researchers have reported various cannabinoids, especially cannabidiol, as a promising approach to CVDs; hence, the purpose of this review is to summarize and update the cardiovascular actions of the most potent phytocannabinoids and the potential therapeutic role of ECS in CVDs, including ischemic reperfusion injury, arrhythmia, heart failure as well as hypertension.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223221143239"},"PeriodicalIF":3.3,"publicationDate":"2023-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/58/10.1177_20406223221143239.PMC9830002.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10528018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing a flow-controlled STA-MCA anastomosis based on the Hagen-Poiseuille law for preventing postoperative hyperperfusion in adult moyamoya disease. 基于Hagen-Poiseuille定律的血流控制STA-MCA吻合预防成人烟雾病术后高灌注
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231181492
Miao Hu, Jin Yu, Jianjian Zhang, Jincao Chen

Background: Technical improvements for preventing postoperative symptomatic cerebral hyperperfusion (CHP) during superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis for moyamoya disease (MMD) were seldom reported.

Objectives: The aim of this study was to investigate the significance of application of a novel flow-controlled concept which voluntarily reduces the hemodynamic difference between the donor and recipient arteries based on the Hagen-Poiseuille law when performing direct anastomoses of recipient parasylvian cortical arteries (PSCAs) with anterograde hemodynamic sources from the MCA (M-PSCAs) in adult MMD.

Design: This was a retrospective observational study.

Methods: Direct anastomoses of recipient M-PSCAs were performed on 89 symptomatic hemispheres in 82 adult MMD patients in our hospital from January 2020 to June 2021. They were divided into the flow-controlled group (patients who received direct anastomosis under designed flow-controlled principles) and non-flow-controlled group (patients who received conventional direct anastomosis to obtain maximum flow). The patients' basic characteristics and incidence of postoperative CHP were compared between the two groups. Risk factors for occurrence of postoperative CHP were analyzed.

Results: Overall, 36 hemispheres were included in the non-flow-controlled group and 53 in flow-controlled group. The incidences of postoperative focal (22.6%) and symptomatic CHP (5.7%) in the flow-controlled group were significantly lower than those (focal, 52.8%; symptomatic, 25.0%) in the non-flow-controlled group (p = 0.003 and 0.009, respectively). Multivariate analysis revealed that the flow-controlled concept was significantly associated with the development of focal (p = 0.005) and symptomatic (p = 0.012) CHP.

Conclusion: The flow-controlled STA-MCA anastomosis can significantly decrease the incidence of postoperative CHP during direct anastomoses of recipient M-PSCAs in adult MMD.

背景:预防烟雾病(MMD)术后颞浅动脉-大脑中动脉(STA-MCA)吻合术中症状性脑高灌注(CHP)的技术改进鲜有报道。目的:本研究的目的是探讨在成人烟雾病患者中,在直接吻合受者皮质旁动脉(PSCAs)与MCA顺行血流动力源(M-PSCAs)时,应用一种基于hagan - poiseuille定律的新型血流控制概念,主动减少供体和受体动脉之间的血流动力学差异的意义。设计:这是一项回顾性观察性研究。方法:于2020年1月至2021年6月对我院82例成人烟雾病患者89个症状半球进行受体m - psca直接吻合。将患者分为流量控制组(按照设计的流量控制原则进行直接吻合)和非流量控制组(采用常规直接吻合以获得最大流量)。比较两组患者的基本特征及术后CHP发生率。分析术后CHP发生的危险因素。结果:无血流控制组共36个脑半球,血流控制组共53个。血流控制组的术后局灶发生率(22.6%)和症状性CHP发生率(5.7%)明显低于(局灶,52.8%;无血流控制组有症状(25.0%)(p分别= 0.003和0.009)。多因素分析显示,血流控制概念与局灶性CHP (p = 0.005)和症状性CHP (p = 0.012)的发展显著相关。结论:流量控制STA-MCA吻合术可显著降低成人烟雾病受体m - psca直接吻合术后CHP的发生率。
{"title":"Designing a flow-controlled STA-MCA anastomosis based on the Hagen-Poiseuille law for preventing postoperative hyperperfusion in adult moyamoya disease.","authors":"Miao Hu,&nbsp;Jin Yu,&nbsp;Jianjian Zhang,&nbsp;Jincao Chen","doi":"10.1177/20406223231181492","DOIUrl":"https://doi.org/10.1177/20406223231181492","url":null,"abstract":"<p><strong>Background: </strong>Technical improvements for preventing postoperative symptomatic cerebral hyperperfusion (CHP) during superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis for moyamoya disease (MMD) were seldom reported.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the significance of application of a novel flow-controlled concept which voluntarily reduces the hemodynamic difference between the donor and recipient arteries based on the Hagen-Poiseuille law when performing direct anastomoses of recipient parasylvian cortical arteries (PSCAs) with anterograde hemodynamic sources from the MCA (M-PSCAs) in adult MMD.</p><p><strong>Design: </strong>This was a retrospective observational study.</p><p><strong>Methods: </strong>Direct anastomoses of recipient M-PSCAs were performed on 89 symptomatic hemispheres in 82 adult MMD patients in our hospital from January 2020 to June 2021. They were divided into the flow-controlled group (patients who received direct anastomosis under designed flow-controlled principles) and non-flow-controlled group (patients who received conventional direct anastomosis to obtain maximum flow). The patients' basic characteristics and incidence of postoperative CHP were compared between the two groups. Risk factors for occurrence of postoperative CHP were analyzed.</p><p><strong>Results: </strong>Overall, 36 hemispheres were included in the non-flow-controlled group and 53 in flow-controlled group. The incidences of postoperative focal (22.6%) and symptomatic CHP (5.7%) in the flow-controlled group were significantly lower than those (focal, 52.8%; symptomatic, 25.0%) in the non-flow-controlled group (<i>p</i> = 0.003 and 0.009, respectively). Multivariate analysis revealed that the flow-controlled concept was significantly associated with the development of focal (<i>p</i> = 0.005) and symptomatic (<i>p</i> = 0.012) CHP.</p><p><strong>Conclusion: </strong>The flow-controlled STA-MCA anastomosis can significantly decrease the incidence of postoperative CHP during direct anastomoses of recipient M-PSCAs in adult MMD.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231181492"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/ea/10.1177_20406223231181492.PMC10350771.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impact of local drug delivery and natural agents as new target strategies against periodontitis: new challenges for personalized therapeutic approach. 局部药物传递和天然药物作为治疗牙周炎的新目标策略的影响:个性化治疗方法的新挑战。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231191043
Gaia Viglianisi, Simona Santonocito, Saturnino Marco Lupi, Mariacristina Amato, Gianrico Spagnuolo, Paolo Pesce, Gaetano Isola

Periodontitis is a persistent inflammation of the soft tissue around the teeth that affects 60% of the population in the globe. The self-maintenance of the inflammatory process can cause periodontal damage from the alveolar bone resorption to tooth loss in order to contrast the effects of periodontitis, the main therapy used is scaling and root planing (SRP). At the same time, studying the physiopathology of periodontitis has shown the possibility of using a local drug delivery system as an adjunctive therapy. Using local drug delivery devices in conjunction with SRP therapy for periodontitis is a potential tool since it increases drug efficacy and minimizes negative effects by managing drug release. This review emphasized how the use of local drug delivery agents and natural agents could be promising adjuvants for the treatment of periodontitis patients affected or not by cardiovascular disease, diabetes, and other system problems. Moreover, the review evidences the current issues and new ideas that can inspire potential later study for both basic research and clinical practice for a tailored approach.

牙周炎是一种牙齿周围软组织的持续性炎症,影响着全球60%的人口。炎症过程的自我维持可引起牙周损伤,从牙槽骨吸收到牙齿脱落,为了与牙周炎的影响形成对比,目前使用的主要治疗方法是刮治和牙根规划(SRP)。同时,对牙周炎的生理病理研究表明,局部给药系统作为辅助治疗的可能性。结合SRP治疗牙周炎,使用局部给药装置是一种潜在的工具,因为它可以通过控制药物释放来提高药物疗效并最大限度地减少负面影响。这篇综述强调了局部药物递送剂和天然药物的使用如何成为治疗牙周炎患者的有希望的辅助剂,无论是否受心血管疾病、糖尿病和其他系统问题的影响。此外,该综述还证明了当前存在的问题和新的想法,可以为基础研究和临床实践提供潜在的启发。
{"title":"Impact of local drug delivery and natural agents as new target strategies against periodontitis: new challenges for personalized therapeutic approach.","authors":"Gaia Viglianisi,&nbsp;Simona Santonocito,&nbsp;Saturnino Marco Lupi,&nbsp;Mariacristina Amato,&nbsp;Gianrico Spagnuolo,&nbsp;Paolo Pesce,&nbsp;Gaetano Isola","doi":"10.1177/20406223231191043","DOIUrl":"https://doi.org/10.1177/20406223231191043","url":null,"abstract":"<p><p>Periodontitis is a persistent inflammation of the soft tissue around the teeth that affects 60% of the population in the globe. The self-maintenance of the inflammatory process can cause periodontal damage from the alveolar bone resorption to tooth loss in order to contrast the effects of periodontitis, the main therapy used is scaling and root planing (SRP). At the same time, studying the physiopathology of periodontitis has shown the possibility of using a local drug delivery system as an adjunctive therapy. Using local drug delivery devices in conjunction with SRP therapy for periodontitis is a potential tool since it increases drug efficacy and minimizes negative effects by managing drug release. This review emphasized how the use of local drug delivery agents and natural agents could be promising adjuvants for the treatment of periodontitis patients affected or not by cardiovascular disease, diabetes, and other system problems. Moreover, the review evidences the current issues and new ideas that can inspire potential later study for both basic research and clinical practice for a tailored approach.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231191043"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/77/10.1177_20406223231191043.PMC10501082.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Systemic monotherapy with acitretin for erythrodermic psoriasis: results of a retrospective study of 81 patients. 红皮病银屑病的全身单药治疗:81例回顾性研究的结果。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231178412
Chenyang Yu, Chao Wu, Yuyan Yang, Hongzhong Jin

Background: Erythrodermic psoriasis (EP) remains challenging to manage because it is rare and has complex complications. Although acitretin is recommended as an appropriate choice for EP, there is a lack of large-scale evidence.

Objectives: This study aims to assess the efficacy and safety of acitretin as systemic monotherapy in EP patients.

Design: We retrospectively analyzed data from patients with EP who received at least 3 months of acitretin as systemic monotherapy during hospitalization and out-patient follow-up from January 2005 to May 2021 at the Peking Union Medical College Hospital, China.

Methods: The efficacy was clinically evaluated after 1, 2, 4, and 12 weeks of treatment, which was classified as a good response (>75% of lesions cleared), partial response (50%-75% cleared), moderate response (25-50% cleared), or no response (<25% cleared). Safety was assessed on the basis of physical examination results and significant changes in laboratory examination results after 12 weeks of treatment.

Results: Overall, 81 patients (79.0% men; mean age, 47.9 years) were included. The acitretin dose ranged from 20 to 60 mg/day (0.3 to 0.8 mg/kg/day). The rates of good, partial, and moderate responses were 0.0%, 2.5%, and 42.0% at 1 week; 3.7%, 34.6%, and 61.7% at 2 weeks; 29.6%, 58.0%, and 12.4% at 4 weeks; and 85.2%, 13.6%, and 1.2% at 12 weeks after treatment initiation, respectively. EP patients transformed from psoriasis vulgaris showed a higher good/partial response rate compared with that of EP patients that developed from pustular or articular psoriasis (44.6% vs. 14.3%, p = 0.035). Patients with concurrent infection showed a lower rate of good/partial response compared with that of those without concurrent infection (16.7% vs. 44.4%, p = 0.049). Adverse effects were seen in 45 (55.6%) patients in 12 weeks, and dyslipidemia (n = 31; 38.3%), xerosis (n = 24; 29.6%), and elevated liver enzymes (n = 6; 7.4%) were most commonly reported. Twenty-three patients were followed up for over 3 years, and six (26.1%) patients had EP recurrence.

Conclusions: Acitretin as a systemic monotherapy showed satisfactory effectiveness for EP, especially in patients developed from psoriasis vulgaris and without infection.

背景:红皮病性牛皮癣(EP)仍然具有挑战性,因为它是罕见的,有复杂的并发症。虽然阿维素被推荐为治疗EP的合适选择,但缺乏大规模的证据。目的:本研究旨在评估阿维a素作为全身单药治疗EP患者的有效性和安全性。设计:我们回顾性分析2005年1月至2021年5月在中国北京协和医院住院和门诊随访期间接受至少3个月阿维甲素系统性单药治疗的EP患者的数据。方法:在治疗1、2、4、12周后进行临床疗效评价,分为良好反应(>75%的病灶清除率)、部分反应(50% ~ 75%清除率)、中度反应(25 ~ 50%清除率)和无反应(结果:总体上,81例患者(79.0%男性;平均年龄47.9岁)。阿维素剂量为20 ~ 60mg /天(0.3 ~ 0.8 mg/kg/天)。1周时,良好、部分和中度缓解率分别为0.0%、2.5%和42.0%;2周时分别为3.7%、34.6%和61.7%;4周时分别为29.6%、58.0%和12.4%;治疗开始后12周,分别为85.2%、13.6%和1.2%。寻常型银屑病转化为EP患者的良好/部分缓解率高于脓疱型或关节型银屑病转化为EP患者(44.6% vs. 14.3%, p = 0.035)。并发感染患者的良好/部分缓解率低于未并发感染患者(16.7% vs. 44.4%, p = 0.049)。12周内出现不良反应45例(55.6%),血脂异常(n = 31;38.3%),干枯病(n = 24;29.6%),肝酶升高(n = 6;7.4%)最为常见。23例患者随访3年以上,EP复发6例(26.1%)。结论:阿维a作为系统性单药治疗EP的效果令人满意,特别是对于寻常型银屑病和无感染的患者。
{"title":"Systemic monotherapy with acitretin for erythrodermic psoriasis: results of a retrospective study of 81 patients.","authors":"Chenyang Yu,&nbsp;Chao Wu,&nbsp;Yuyan Yang,&nbsp;Hongzhong Jin","doi":"10.1177/20406223231178412","DOIUrl":"https://doi.org/10.1177/20406223231178412","url":null,"abstract":"<p><strong>Background: </strong>Erythrodermic psoriasis (EP) remains challenging to manage because it is rare and has complex complications. Although acitretin is recommended as an appropriate choice for EP, there is a lack of large-scale evidence.</p><p><strong>Objectives: </strong>This study aims to assess the efficacy and safety of acitretin as systemic monotherapy in EP patients.</p><p><strong>Design: </strong>We retrospectively analyzed data from patients with EP who received at least 3 months of acitretin as systemic monotherapy during hospitalization and out-patient follow-up from January 2005 to May 2021 at the Peking Union Medical College Hospital, China.</p><p><strong>Methods: </strong>The efficacy was clinically evaluated after 1, 2, 4, and 12 weeks of treatment, which was classified as a good response (>75% of lesions cleared), partial response (50%-75% cleared), moderate response (25-50% cleared), or no response (<25% cleared). Safety was assessed on the basis of physical examination results and significant changes in laboratory examination results after 12 weeks of treatment.</p><p><strong>Results: </strong>Overall, 81 patients (79.0% men; mean age, 47.9 years) were included. The acitretin dose ranged from 20 to 60 mg/day (0.3 to 0.8 mg/kg/day). The rates of good, partial, and moderate responses were 0.0%, 2.5%, and 42.0% at 1 week; 3.7%, 34.6%, and 61.7% at 2 weeks; 29.6%, 58.0%, and 12.4% at 4 weeks; and 85.2%, 13.6%, and 1.2% at 12 weeks after treatment initiation, respectively. EP patients transformed from psoriasis vulgaris showed a higher good/partial response rate compared with that of EP patients that developed from pustular or articular psoriasis (44.6% <i>vs.</i> 14.3%, <i>p</i> = 0.035). Patients with concurrent infection showed a lower rate of good/partial response compared with that of those without concurrent infection (16.7% <i>vs.</i> 44.4%, <i>p</i> = 0.049). Adverse effects were seen in 45 (55.6%) patients in 12 weeks, and dyslipidemia (<i>n</i> = 31; 38.3%), xerosis (<i>n</i> = 24; 29.6%), and elevated liver enzymes (<i>n</i> = 6; 7.4%) were most commonly reported. Twenty-three patients were followed up for over 3 years, and six (26.1%) patients had EP recurrence.</p><p><strong>Conclusions: </strong>Acitretin as a systemic monotherapy showed satisfactory effectiveness for EP, especially in patients developed from psoriasis vulgaris and without infection.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231178412"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/8b/10.1177_20406223231178412.PMC10286161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10291737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The early diagnostic value of optical coherence tomography (OCT) and OCT angiography in thyroid-associated ophthalmopathy. 光学相干断层扫描(OCT)和OCT血管造影对甲状腺相关性眼病的早期诊断价值。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231166802
Bei Xu, Sha Wang, Lu Chen, Jia Tan

Background: The retinal microvascular density changes have been identified in thyroid-associated ophthalmopathy (TAO) patients. Whereas a lack of research has been done on the diagnostic ability of optical coherence tomography (OCT) combined with optical coherence tomography angiography (OCTA) parameters.

Objectives: This study aims to evaluate the retina perfusion variations in eyes with active and stable TAO and its diagnostic abilities using OCT and OCTA.

Design: This is cohort longitudinal retrospective study.

Methods: A total of 51 patients with TAO and 39 healthy controls (HCs) were recruited. The TAO eyes were divided into active and stable stage groups. The foveal avascular zone (FAZ), macular perfusion density (mPD), and peripapillary PD were measured by OCTA. The peripapillary retinal nerve fiber layer (RNFL), central retinal thickness (CRT), and whole macular volume (wMV) were measured by OCT. Visual evoked potential (VEP) and visual field (VF) were also assessed.

Results: The mPD of the superficial retinal capillary plexus (SRCP) was significantly different in all subfields among active, stable, and HC groups (p < 0.05) except for the temporal inner (p = 0.137), and the active group achieved the lowest PD. The FAZ size increased significantly in the active and stable groups compared with the HC group (p < 0.001). Significant difference was observed in mPD of deep retinal capillary plexus (DRCP) in all quadrants among three groups (p < 0.05). Moreover, PD parameters of optic nerve head (ONH) and radial peripapillary capillary plexus (RPCP) showed a different trend among three groups (p < 0.05). The r-value of visual field-mean deviation (VF-MD) of TAO with DRCP-whole PD (wPD) and RPCP-wPD was 0.421 and 0.299, respectively (p < 0.05). The DRCP-wPD in OCTA and RNFL in OCT were significantly higher in area under the receiver operating characteristic curve (AUC) than that of HC eyes.

Conclusion: OCT and OCTA can noninvasively detect the peripapillary and macular changes in various stages of TAO patients, and it might be a high diagnostic value tool to monitor the TAO progression.

背景:甲状腺相关性眼病(TAO)患者视网膜微血管密度改变已被确认。而光学相干断层扫描(OCT)结合光学相干断层扫描血管造影(OCTA)参数的诊断能力研究缺乏。目的:评价活动性和稳定性TAO眼视网膜灌注变化及其OCT和OCTA诊断能力。设计:这是一项队列纵向回顾性研究。方法:共招募51例TAO患者和39例健康对照(hc)。TAO眼分为活跃和稳定两组。OCTA测量中央凹无血管区(FAZ)、黄斑灌注密度(mPD)和乳头周围PD。oct检测视网膜乳头周围神经纤维层(RNFL)、视网膜中央厚度(CRT)、黄斑整体体积(wMV),并评估视觉诱发电位(VEP)和视野(VF)。结果:活跃组、稳定组和HC组视网膜浅毛细血管丛(SRCP)各子野mPD差异有统计学意义(p p = 0.137),且活跃组PD最低。与HC组相比,活动组和稳定组的FAZ大小明显增加(p p p -wPD和rcpp -wPD的视野平均偏差(VF-MD) r值分别为0.421和0.299)。结论:OCT和OCTA可以无创地检测TAO患者各阶段的乳头周围和黄斑变化,可能是一种具有较高诊断价值的监测TAO进展的工具。
{"title":"The early diagnostic value of optical coherence tomography (OCT) and OCT angiography in thyroid-associated ophthalmopathy.","authors":"Bei Xu,&nbsp;Sha Wang,&nbsp;Lu Chen,&nbsp;Jia Tan","doi":"10.1177/20406223231166802","DOIUrl":"https://doi.org/10.1177/20406223231166802","url":null,"abstract":"<p><strong>Background: </strong>The retinal microvascular density changes have been identified in thyroid-associated ophthalmopathy (TAO) patients. Whereas a lack of research has been done on the diagnostic ability of optical coherence tomography (OCT) combined with optical coherence tomography angiography (OCTA) parameters.</p><p><strong>Objectives: </strong>This study aims to evaluate the retina perfusion variations in eyes with active and stable TAO and its diagnostic abilities using OCT and OCTA.</p><p><strong>Design: </strong>This is cohort longitudinal retrospective study.</p><p><strong>Methods: </strong>A total of 51 patients with TAO and 39 healthy controls (HCs) were recruited. The TAO eyes were divided into active and stable stage groups. The foveal avascular zone (FAZ), macular perfusion density (mPD), and peripapillary PD were measured by OCTA. The peripapillary retinal nerve fiber layer (RNFL), central retinal thickness (CRT), and whole macular volume (wMV) were measured by OCT. Visual evoked potential (VEP) and visual field (VF) were also assessed.</p><p><strong>Results: </strong>The mPD of the superficial retinal capillary plexus (SRCP) was significantly different in all subfields among active, stable, and HC groups (<i>p</i> < 0.05) except for the temporal inner (<i>p</i> = 0.137), and the active group achieved the lowest PD. The FAZ size increased significantly in the active and stable groups compared with the HC group (<i>p</i> < 0.001). Significant difference was observed in mPD of deep retinal capillary plexus (DRCP) in all quadrants among three groups (<i>p</i> < 0.05). Moreover, PD parameters of optic nerve head (ONH) and radial peripapillary capillary plexus (RPCP) showed a different trend among three groups (<i>p</i> < 0.05). The <i>r</i>-value of visual field-mean deviation (VF-MD) of TAO with DRCP-whole PD (wPD) and RPCP-wPD was 0.421 and 0.299, respectively (<i>p</i> < 0.05). The DRCP-wPD in OCTA and RNFL in OCT were significantly higher in area under the receiver operating characteristic curve (AUC) than that of HC eyes.</p><p><strong>Conclusion: </strong>OCT and OCTA can noninvasively detect the peripapillary and macular changes in various stages of TAO patients, and it might be a high diagnostic value tool to monitor the TAO progression.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231166802"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/37/10.1177_20406223231166802.PMC10176590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shared decision-making in multiple sclerosis physical symptomatic care: a systematic review. 共同决策在多发性硬化症物理症状护理:系统回顾。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231172920
Aliza Bitton Ben-Zacharia, Jong-Mi Lee, Jennifer S Kahle, Bonnie Lord

Background: Multiple sclerosis (MS) is a chronic autoimmune inflammatory, demyelinating, and neurodegenerative disease affecting young adults. People with MS are highly interested in engaging in physical symptom management and decision-making but are often not actively engaged in symptom management discussions. Research examining the benefit of shared decision-making in the management of physical MS symptoms is sparse.

Objectives: This study aimed to identify and synthesize the evidence on the use of shared decision-making in physical MS symptom management.

Design: This study is a systematic review of published evidence on the use of shared decision-making in physical MS symptom management.

Data sources and methods: MEDLINE, CINAHL, EMBASE, and CENTRAL databases were searched in April 2021, June 2022, and April 2, 2023, for primary, peer-reviewed studies of shared decision-making in the management of MS physical symptoms. Citations were screened, data extracted, and study quality assessed according to Cochrane guidelines for systematic reviews, including risk of bias assessment. Statistical synthesis of the included study results was not appropriate; results were summarized in a nonstatistical manner using the vote-counting method to estimate beneficial versus harmful effects.

Results: Of 679 citations, 15 studies met the inclusion criteria. Six studies addressed shared decision-making in the management of pain, spasms, neurogenic bladder, fatigue, gait disorder, and/or balance issues, and nine studies addressed physical symptoms in general. One study was a randomized controlled trial; most studies were observational studies. All study results and study author conclusions indicated that shared decision-making is important to the effective management of physical MS symptoms. No study results suggested that shared decision-making was harmful or delayed the management of physical MS symptoms.

Conclusion: Reported results consistently indicate that shared decision-making is important in effective MS symptomatic care. Further rigorous randomized controlled trials are warranted to investigate the effectiveness of shared decision-making associated with MS physical symptomatic care.

Registration: PROSPERO: CRD42023396270.

背景:多发性硬化症(MS)是一种影响年轻人的慢性自身免疫性炎症、脱髓鞘和神经退行性疾病。多发性硬化症患者对参与身体症状管理和决策非常感兴趣,但通常不积极参与症状管理的讨论。关于共同决策在多发性硬化症症状管理中的益处的研究很少。目的:本研究旨在识别和综合在MS症状管理中使用共同决策的证据。设计:本研究是对已发表的关于在MS症状管理中使用共同决策的证据进行系统回顾。数据来源和方法:检索MEDLINE、CINAHL、EMBASE和CENTRAL数据库,检索于2021年4月、2022年6月和2023年4月2日进行的关于MS身体症状管理中共同决策的初步同行评议研究。根据Cochrane系统评价指南筛选引文、提取数据并评估研究质量,包括偏倚风险评估。纳入研究结果的统计综合不恰当;结果以非统计的方式总结,使用选票计数方法来估计有益和有害的影响。结果:679篇引用中,有15篇符合纳入标准。6项研究涉及疼痛、痉挛、神经源性膀胱、疲劳、步态障碍和/或平衡问题管理中的共同决策,9项研究涉及一般的身体症状。一项研究是随机对照试验;大多数研究都是观察性研究。所有的研究结果和研究作者的结论都表明,共同决策对MS身体症状的有效管理很重要。没有研究结果表明共同决策是有害的或延迟MS物理症状的管理。结论:报告的结果一致表明,共同决策对有效的MS症状治疗很重要。需要进一步严格的随机对照试验来调查与MS身体症状护理相关的共同决策的有效性。注册:普洛斯彼罗:CRD42023396270。
{"title":"Shared decision-making in multiple sclerosis physical symptomatic care: a systematic review.","authors":"Aliza Bitton Ben-Zacharia,&nbsp;Jong-Mi Lee,&nbsp;Jennifer S Kahle,&nbsp;Bonnie Lord","doi":"10.1177/20406223231172920","DOIUrl":"https://doi.org/10.1177/20406223231172920","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a chronic autoimmune inflammatory, demyelinating, and neurodegenerative disease affecting young adults. People with MS are highly interested in engaging in physical symptom management and decision-making but are often not actively engaged in symptom management discussions. Research examining the benefit of shared decision-making in the management of physical MS symptoms is sparse.</p><p><strong>Objectives: </strong>This study aimed to identify and synthesize the evidence on the use of shared decision-making in physical MS symptom management.</p><p><strong>Design: </strong>This study is a systematic review of published evidence on the use of shared decision-making in physical MS symptom management.</p><p><strong>Data sources and methods: </strong>MEDLINE, CINAHL, EMBASE, and CENTRAL databases were searched in April 2021, June 2022, and April 2, 2023, for primary, peer-reviewed studies of shared decision-making in the management of MS physical symptoms. Citations were screened, data extracted, and study quality assessed according to Cochrane guidelines for systematic reviews, including risk of bias assessment. Statistical synthesis of the included study results was not appropriate; results were summarized in a nonstatistical manner using the vote-counting method to estimate beneficial versus harmful effects.</p><p><strong>Results: </strong>Of 679 citations, 15 studies met the inclusion criteria. Six studies addressed shared decision-making in the management of pain, spasms, neurogenic bladder, fatigue, gait disorder, and/or balance issues, and nine studies addressed physical symptoms in general. One study was a randomized controlled trial; most studies were observational studies. All study results and study author conclusions indicated that shared decision-making is important to the effective management of physical MS symptoms. No study results suggested that shared decision-making was harmful or delayed the management of physical MS symptoms.</p><p><strong>Conclusion: </strong>Reported results consistently indicate that shared decision-making is important in effective MS symptomatic care. Further rigorous randomized controlled trials are warranted to investigate the effectiveness of shared decision-making associated with MS physical symptomatic care.</p><p><strong>Registration: </strong>PROSPERO: CRD42023396270.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231172920"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/0a/10.1177_20406223231172920.PMC10265321.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10351451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinguishing bronchoscopically observed anatomical positions of airway under by convolutional neural network. 用卷积神经网络识别支气管镜下气道解剖位置。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231181495
Chongxiang Chen, Felix Jf Herth, Yingnan Zuo, Hongjia Li, Xinyuan Liang, Yaqing Chen, Jiangtao Ren, Wenhua Jian, Changhao Zhong, Shiyue Li

Background: Artificial intelligence (AI) technology has been used for finding lesions via gastrointestinal endoscopy. However, there were few AI-associated studies that discuss bronchoscopy.

Objectives: To use convolutional neural network (CNN) to recognize the observed anatomical positions of the airway under bronchoscopy.

Design: We designed the study by comparing the imaging data of patients undergoing bronchoscopy from March 2022 to October 2022 by using EfficientNet (one of the CNNs) and U-Net.

Methods: Based on the inclusion and exclusion criteria, 1527 clear images of normal anatomical positions of the airways from 200 patients were used for training, and 475 clear images from 72 patients were utilized for validation. Further, 20 bronchoscopic videos of examination procedures in another 20 patients with normal airway structures were used to extract the bronchoscopic images of normal anatomical positions to evaluate the accuracy for the model. Finally, 21 respiratory doctors were enrolled for the test of recognizing corrected anatomical positions using the validating datasets.

Results: In all, 1527 bronchoscopic images of 200 patients with nine anatomical positions of the airway, including carina, right main bronchus, right upper lobe bronchus, right intermediate bronchus, right middle lobe bronchus, right lower lobe bronchus, left main bronchus, left upper lobe bronchus, and left lower lobe bronchus, were used for supervised machine learning and training, and 475 clear bronchoscopic images of 72 patients were used for validation. The mean accuracy of recognizing these 9 positions was 91% (carina: 98%, right main bronchus: 98%, right intermediate bronchus: 90%, right upper lobe bronchus: 91%, right middle lobe bronchus 92%, right lower lobe bronchus: 83%, left main bronchus: 89%, left upper bronchus: 91%, left lower bronchus: 76%). The area under the curves for these nine positions were >0.98. In addition, the accuracy of extracting the images via the video by the trained model was 94.7%. We also conducted a deep learning study to segment 10 segment bronchi in right lung, and 8 segment bronchi in Left lung. Because of the problem of radial depth, only segment bronchi distributions below right upper bronchus and right middle bronchus could be correctly recognized. The accuracy of recognizing was 84.33 ± 7.52% by doctors receiving interventional pulmonology education in our hospital over 6 months.

Conclusion: Our study proved that AI technology can be used to distinguish the normal anatomical positions of the airway, and the model we trained could extract the corrected images via the video to help standardize data collection and control quality.

背景:人工智能(AI)技术已被用于通过胃肠道内窥镜发现病变。然而,很少有人工智能相关的研究讨论支气管镜检查。目的:利用卷积神经网络(CNN)识别支气管镜下观察到的气道解剖位置。设计:我们通过使用cnn之一的EfficientNet和U-Net比较2022年3月至2022年10月接受支气管镜检查的患者的影像学数据来设计研究。方法:根据纳入和排除标准,选取200例患者气道正常解剖位置的1527张清晰图像进行训练,72例患者的475张清晰图像进行验证。此外,我们还使用另外20例气道结构正常的患者的20个支气管镜检查过程视频,提取正常解剖位置的支气管镜图像,以评估模型的准确性。最后,21名呼吸内科医生参与了使用验证数据集识别正确解剖位置的测试。结果:200例患者共1527张支气管镜图像用于监督机器学习和训练,包括隆突、右侧主支气管、右侧上叶支气管、右侧中间支气管、右侧中叶支气管、右侧下叶支气管、左侧主支气管、左侧上叶支气管和左侧下叶支气管9个气道解剖位置,并使用72例患者的475张支气管镜清晰图像进行验证。9个位置的平均识别准确率为91%(隆突:98%,右侧主支气管:98%,右侧中间支气管:90%,右侧上叶支气管:91%,右侧中叶支气管92%,右侧下叶支气管:83%,左侧主支气管:89%,左侧上支气管:91%,左侧下支气管:76%)。这9个位置的曲线下面积均>0.98。此外,训练后的模型通过视频提取图像的准确率为94.7%。我们还对右肺10段支气管和左肺8段支气管进行了深度学习研究。由于径向深度的问题,只能正确识别右上支气管和右中支气管以下的段支气管分布。在我院接受介入性肺科教育6个月以上医师的识别准确率为84.33±7.52%。结论:我们的研究证明AI技术可以用于区分气道的正常解剖位置,我们训练的模型可以通过视频提取校正后的图像,有助于规范数据收集和控制质量。
{"title":"Distinguishing bronchoscopically observed anatomical positions of airway under by convolutional neural network.","authors":"Chongxiang Chen,&nbsp;Felix Jf Herth,&nbsp;Yingnan Zuo,&nbsp;Hongjia Li,&nbsp;Xinyuan Liang,&nbsp;Yaqing Chen,&nbsp;Jiangtao Ren,&nbsp;Wenhua Jian,&nbsp;Changhao Zhong,&nbsp;Shiyue Li","doi":"10.1177/20406223231181495","DOIUrl":"https://doi.org/10.1177/20406223231181495","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) technology has been used for finding lesions <i>via</i> gastrointestinal endoscopy. However, there were few AI-associated studies that discuss bronchoscopy.</p><p><strong>Objectives: </strong>To use convolutional neural network (CNN) to recognize the observed anatomical positions of the airway under bronchoscopy.</p><p><strong>Design: </strong>We designed the study by comparing the imaging data of patients undergoing bronchoscopy from March 2022 to October 2022 by using EfficientNet (one of the CNNs) and U-Net.</p><p><strong>Methods: </strong>Based on the inclusion and exclusion criteria, 1527 clear images of normal anatomical positions of the airways from 200 patients were used for training, and 475 clear images from 72 patients were utilized for validation. Further, 20 bronchoscopic videos of examination procedures in another 20 patients with normal airway structures were used to extract the bronchoscopic images of normal anatomical positions to evaluate the accuracy for the model. Finally, 21 respiratory doctors were enrolled for the test of recognizing corrected anatomical positions using the validating datasets.</p><p><strong>Results: </strong>In all, 1527 bronchoscopic images of 200 patients with nine anatomical positions of the airway, including carina, right main bronchus, right upper lobe bronchus, right intermediate bronchus, right middle lobe bronchus, right lower lobe bronchus, left main bronchus, left upper lobe bronchus, and left lower lobe bronchus, were used for supervised machine learning and training, and 475 clear bronchoscopic images of 72 patients were used for validation. The mean accuracy of recognizing these 9 positions was 91% (carina: 98%, right main bronchus: 98%, right intermediate bronchus: 90%, right upper lobe bronchus: 91%, right middle lobe bronchus 92%, right lower lobe bronchus: 83%, left main bronchus: 89%, left upper bronchus: 91%, left lower bronchus: 76%). The area under the curves for these nine positions were >0.98. In addition, the accuracy of extracting the images <i>via</i> the video by the trained model was 94.7%. We also conducted a deep learning study to segment 10 segment bronchi in right lung, and 8 segment bronchi in Left lung. Because of the problem of radial depth, only segment bronchi distributions below right upper bronchus and right middle bronchus could be correctly recognized. The accuracy of recognizing was 84.33 ± 7.52% by doctors receiving interventional pulmonology education in our hospital over 6 months.</p><p><strong>Conclusion: </strong>Our study proved that AI technology can be used to distinguish the normal anatomical positions of the airway, and the model we trained could extract the corrected images <i>via</i> the video to help standardize data collection and control quality.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231181495"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/9b/10.1177_20406223231181495.PMC10457519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10100822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk factors for the long-term incidence and progression of knee osteoarthritis in older adults: role of nonsurgical injury. 老年人膝骨关节炎长期发病率和进展的危险因素:非手术损伤的作用。
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231169715
Jean-Pierre Pelletier, Patrice Paiement, Marc Dorais, Jean-Pierre Raynauld, Johanne Martel-Pelletier

Background: For one of the most chronic medical conditions, osteoarthritis, uncertainties remain on the impact of injury chronology, the role of repeat injury on the incidence/progression of this disease and the need for knee arthroplasty.

Objectives: To explore, in an older adult population, how nonsurgical knee injuries relate to osteoarthritis incidence/progression and the weight of independent risk factors for arthroplasty.

Design: A cohort study design evaluates the long-term impact of injuries on knee osteoarthritis outcomes.

Methods: Knees with no prior injury (n = 6358) and with at least one injury (n = 819) ⩽20 years before study inclusion were from the Osteoarthritis Initiative cohort. Sociodemographic, clinical and structural [X-ray, magnetic resonance imaging (MRI)] data at study inclusion and changes within 96 months were analysed. Statistics included a mixed model for repeated measurements, generalized estimating equations and multivariable Cox regression with covariates.

Results: At inclusion, knees with prior injury demonstrated greater incidence and severity of osteoarthritis (p ⩽ 0.001). At 96 months, there was a greater increase in symptoms [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, p = 0.002], joint space width (JSW, p = 0.039) loss, medial cartilage volume loss (CVL, p ⩽ 0.001) and bone marrow lesion size (BML, p ⩽ 0.049). Knees with/without injury at inclusion but with new ones over time had a pronounced increase in symptoms (all WOMAC scores, p ⩽ 0.001), JSW loss, lateral (without) and medial CVL, lateral (without) and medial meniscal extrusion and medial BML (without; all p ⩽ 0.030). Levels of lateral and medial meniscal extrusion (without) and symptoms (with/without; all WOMAC scores, p ⩽ 0.001) were all accentuated with a repeated new injury. Risk factors associated with the highest knee arthroplasty occurrence are new meniscal extrusion and new injury (p ⩽ 0.001).

Conclusion: This study highlights the importance of nonsurgical knee injury in older adults as an independent risk factor for knee osteoarthritis and arthroplasty. These data will be beneficial in clinical practice as they will help identify individuals at greater risk of significant disease progression and worst disease outcomes for a customized therapeutic approach.

背景:对于最慢性的疾病之一骨关节炎,损伤年表的影响、重复损伤对该疾病的发生/进展的作用以及膝关节置换术的必要性仍然存在不确定性。目的:探讨在老年人群中,非手术性膝关节损伤与骨关节炎发病率/进展的关系以及关节置换术独立危险因素的权重。设计:队列研究设计评估损伤对膝骨关节炎预后的长期影响。方法:研究纳入前≥20年的膝部无损伤(n = 6358)和至少有一次损伤(n = 819)患者均来自骨关节炎倡议队列。研究纳入时的社会人口学、临床和结构[x射线、磁共振成像(MRI)]数据以及96个月内的变化进行了分析。统计学包括重复测量的混合模型、广义估计方程和带有协变量的多变量Cox回归。结果:在纳入时,既往损伤的膝关节表现出更高的骨关节炎发生率和严重程度(p < 0.001)。在96个月时,症状(西安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛,p = 0.002)、关节间隙宽度(JSW, p = 0.039)损失、内侧软骨体积损失(CVL, p < 0.001)和骨髓病变大小(BML, p < 0.049)的增加幅度更大。纳入时有/没有损伤但随着时间的推移有新损伤的膝关节症状明显增加(所有WOMAC评分,p < 0.001), JSW丧失,外侧(没有)和内侧CVL,外侧(没有)和内侧半月板挤压和内侧BML(没有;p < 0.030)。外侧和内侧半月板挤压程度(无)和症状(有/没有;所有WOMAC评分(p < 0.001)均因重复的新损伤而加重。与膝关节置换术发生率最高的危险因素是新的半月板挤压和新的损伤(p < 0.001)。结论:本研究强调了老年人非手术性膝关节损伤作为膝关节骨关节炎和关节置换术的独立危险因素的重要性。这些数据在临床实践中将是有益的,因为它们将有助于识别具有重大疾病进展风险的个体和定制治疗方法的最坏疾病结果。
{"title":"Risk factors for the long-term incidence and progression of knee osteoarthritis in older adults: role of nonsurgical injury.","authors":"Jean-Pierre Pelletier,&nbsp;Patrice Paiement,&nbsp;Marc Dorais,&nbsp;Jean-Pierre Raynauld,&nbsp;Johanne Martel-Pelletier","doi":"10.1177/20406223231169715","DOIUrl":"https://doi.org/10.1177/20406223231169715","url":null,"abstract":"<p><strong>Background: </strong>For one of the most chronic medical conditions, osteoarthritis, uncertainties remain on the impact of injury chronology, the role of repeat injury on the incidence/progression of this disease and the need for knee arthroplasty.</p><p><strong>Objectives: </strong>To explore, in an older adult population, how nonsurgical knee injuries relate to osteoarthritis incidence/progression and the weight of independent risk factors for arthroplasty.</p><p><strong>Design: </strong>A cohort study design evaluates the long-term impact of injuries on knee osteoarthritis outcomes.</p><p><strong>Methods: </strong>Knees with no prior injury (<i>n</i> = 6358) and with at least one injury (<i>n</i> = 819) ⩽20 years before study inclusion were from the Osteoarthritis Initiative cohort. Sociodemographic, clinical and structural [X-ray, magnetic resonance imaging (MRI)] data at study inclusion and changes within 96 months were analysed. Statistics included a mixed model for repeated measurements, generalized estimating equations and multivariable Cox regression with covariates.</p><p><strong>Results: </strong>At inclusion, knees with prior injury demonstrated greater incidence and severity of osteoarthritis (<i>p</i> ⩽ 0.001). At 96 months, there was a greater increase in symptoms [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, <i>p</i> = 0.002], joint space width (JSW, <i>p</i> = 0.039) loss, medial cartilage volume loss (CVL, <i>p</i> ⩽ 0.001) and bone marrow lesion size (BML, <i>p</i> ⩽ 0.049). Knees with/without injury at inclusion but with new ones over time had a pronounced increase in symptoms (all WOMAC scores, <i>p</i> ⩽ 0.001), JSW loss, lateral (without) and medial CVL, lateral (without) and medial meniscal extrusion and medial BML (without; all <i>p</i> ⩽ 0.030). Levels of lateral and medial meniscal extrusion (without) and symptoms (with/without; all WOMAC scores, <i>p</i> ⩽ 0.001) were all accentuated with a repeated new injury. Risk factors associated with the highest knee arthroplasty occurrence are new meniscal extrusion and new injury (<i>p</i> ⩽ 0.001).</p><p><strong>Conclusion: </strong>This study highlights the importance of nonsurgical knee injury in older adults as an independent risk factor for knee osteoarthritis and arthroplasty. These data will be beneficial in clinical practice as they will help identify individuals at greater risk of significant disease progression and worst disease outcomes for a customized therapeutic approach.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231169715"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/c8/10.1177_20406223231169715.PMC10184209.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10290161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype. 恶性血液病患者感染死亡率趋势:不同恶性血液病亚型的差异
IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1177/20406223231173891
Xuejiao Yin, Xuelian Hu, Hongyan Tong, Liangshun You

Background: Infection is the most important cause of non-relapse mortality in hematologic malignancy patients, leading to increased costs and prolonged hospitalization times. However, comprehensive and comparable reports on infection-specific mortality (ISM) trends in hematologic malignancy patients are lacking.

Objectives: We aimed to provide updated ISM trends and factors associated with ISM among hematologic malignancy patients.

Design: This is a retrospective study.

Methods: Patients diagnosed with the five most common hematologic malignancies from 1983 to 2016 from the Surveillance, Epidemiology, and End Results database were included. Joinpoint regression was used to analyze mortality trends.

Results: ISM decreased beginning in 1983, 1988, and 1994, with yearly decreases of -2.1% for acute leukemia (AL), -1.3% for Hodgkin lymphoma (HL), and -14.3% for non-Hodgkin lymphoma (NHL). In contrast, ISM in patients with chronic leukemia (CL) and multiple myeloma (MM) increased dramatically beginning in 2000, with yearly increases of 2.8% and 3.3%, respectively. ISM rates were higher in males than in females across all hematologic malignancy subtypes. The mortality trends significantly differed according to race, age, sex, and stage, which could help in further etiological investigations. Moreover, male sex, older age at diagnosis, black race, and unmarried status were poor prognostic factors for ISM across all hematologic malignancy subtypes.

Conclusion: A promising downward trend in ISM in recent years occurred in patients with AL, HL, and NHL; however, ISM increased dramatically in patients with CL and MM. Our data suggest that risk assessment and careful infection monitoring are recommended for hematologic malignancy patients, particularly those with CL and MM.

背景:感染是恶性血液病患者非复发性死亡的最重要原因,导致费用增加和住院时间延长。然而,关于恶性血液病患者感染特异性死亡率(ISM)趋势的综合和可比较的报告是缺乏的。目的:我们旨在提供血液恶性肿瘤患者ISM的最新趋势和相关因素。设计:这是一项回顾性研究。方法:从监测、流行病学和最终结果数据库中纳入1983 - 2016年诊断为5种最常见血液恶性肿瘤的患者。采用结合点回归分析死亡率趋势。结果:ISM从1983年、1988年和1994年开始下降,急性白血病(AL)年下降2.1%,霍奇金淋巴瘤(HL)年下降1.3%,非霍奇金淋巴瘤(NHL)年下降14.3%。相比之下,慢性白血病(CL)和多发性骨髓瘤(MM)患者的ISM从2000年开始急剧增加,年增长率分别为2.8%和3.3%。在所有血液恶性肿瘤亚型中,男性的ISM发病率高于女性。死亡率趋势因种族、年龄、性别和分期而有显著差异,这有助于进一步的病因调查。此外,男性、诊断时年龄较大、黑人种族和未婚状态是所有血液恶性肿瘤亚型中ISM的不良预后因素。结论:近年来,AL、HL和NHL患者的ISM呈下降趋势;然而,ISM在CL和MM患者中显著增加。我们的数据表明,对于血液恶性肿瘤患者,特别是CL和MM患者,建议进行风险评估和仔细的感染监测。
{"title":"Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype.","authors":"Xuejiao Yin,&nbsp;Xuelian Hu,&nbsp;Hongyan Tong,&nbsp;Liangshun You","doi":"10.1177/20406223231173891","DOIUrl":"https://doi.org/10.1177/20406223231173891","url":null,"abstract":"<p><strong>Background: </strong>Infection is the most important cause of non-relapse mortality in hematologic malignancy patients, leading to increased costs and prolonged hospitalization times. However, comprehensive and comparable reports on infection-specific mortality (ISM) trends in hematologic malignancy patients are lacking.</p><p><strong>Objectives: </strong>We aimed to provide updated ISM trends and factors associated with ISM among hematologic malignancy patients.</p><p><strong>Design: </strong>This is a retrospective study.</p><p><strong>Methods: </strong>Patients diagnosed with the five most common hematologic malignancies from 1983 to 2016 from the Surveillance, Epidemiology, and End Results database were included. Joinpoint regression was used to analyze mortality trends.</p><p><strong>Results: </strong>ISM decreased beginning in 1983, 1988, and 1994, with yearly decreases of -2.1% for acute leukemia (AL), -1.3% for Hodgkin lymphoma (HL), and -14.3% for non-Hodgkin lymphoma (NHL). In contrast, ISM in patients with chronic leukemia (CL) and multiple myeloma (MM) increased dramatically beginning in 2000, with yearly increases of 2.8% and 3.3%, respectively. ISM rates were higher in males than in females across all hematologic malignancy subtypes. The mortality trends significantly differed according to race, age, sex, and stage, which could help in further etiological investigations. Moreover, male sex, older age at diagnosis, black race, and unmarried status were poor prognostic factors for ISM across all hematologic malignancy subtypes.</p><p><strong>Conclusion: </strong>A promising downward trend in ISM in recent years occurred in patients with AL, HL, and NHL; however, ISM increased dramatically in patients with CL and MM. Our data suggest that risk assessment and careful infection monitoring are recommended for hematologic malignancy patients, particularly those with CL and MM.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231173891"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/36/10.1177_20406223231173891.PMC10288445.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10291738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Advances in Chronic Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1